Search

Displaying results 3971 - 3980 of 7284 in total
  1. Drug

    Methenamine

    go.drugbank.com/drugs/DB06799
    ApprovedInvestigationalVet approved

    Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.

    Mixtures: Urin D/S, Prosed/DS
  2. Target

    Prostaglandin E synthase 3

    go.drugbank.com/bio_entities/BE0002480
    TargetHumans

    Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) (PubMed:10922363). Molecular chaperone that localizes to genomic response elements in a hormone-depende...

    Synonyms: Progesterone receptor complex p23
  3. Target

    Proteasome subunit alpha type-2

    go.drugbank.com/bio_entities/BE0003911
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex subunit C3
  4. Target

    Proteasome subunit beta type-7

    go.drugbank.com/bio_entities/BE0003920
    TargetHumans

    Within the 20S core complex, PSMB7 displays a trypsin-like activity … Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.

    Synonyms: Multicatalytic endopeptidase complex chain Z
  5. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.

  6. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. … The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with

  7. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties. … The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate.[L43942] Other forms of pentoxyverine citrate continue to be marketed.

    Mixtures: Exall D, Zotex-D
  8. Target

    Proteasome subunit alpha type-3

    go.drugbank.com/bio_entities/BE0003912
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).

    Synonyms: Multicatalytic endopeptidase complex subunit C8
  9. Drug

    Glucagon

    go.drugbank.com/drugs/DB00040
    ApprovedInvestigational

    Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. … [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]

    Synonyms: Glucagon (recombinant dna origin)
  10. Drug

    Efalizumab

    go.drugbank.com/drugs/DB00095
    ApprovedWithdrawn

    Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. … The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML).[L43797]